Optical Coherence Tomography of Plaque Erosion: JACC Focus Seminar Part 2/3.
Plaque erosion, a distinct histopathological and clinical entity, accounts for over 30% of acute coronary syndromes (ACS). Optical coherence tomography allows in vivo diagnosis of plaque erosion. Local flow perturbation with activation of Toll-like receptor 2 and CD8+ T cells and subsequent desquamation of endothelium and neutrophil extracellular trap formation contribute to mechanisms of plaque erosion. Compared with ACS patients with plaque rupture, those with plaque erosion are younger, have fewer traditional cardiovascular risk factors, have lower plaque burden, and are more likely to present with non-ST-segment elevation ACS. Early evidence suggests that in patients with ACS caused by plaque erosion, antithrombotic therapy without stenting may be a safe and effective option. Future randomized trials are needed to validate these findings. Clinical studies to develop noninvasive point-of-care biomarkers that distinguish plaque rupture from erosion, and to test novel therapies that target molecular pathways involved in plaque erosion are needed.
['Kolte|Dhaval|D|', 'Yonetsu|Taishi|T|', 'Ye|Jong Chul|JC|', 'Libby|Peter|P|', 'Fuster|Valentin|V|', 'Jang|Ik-Kyung|IK|']
optical coherence tomography plaque erosion acute coronary syndromes coronary thrombosis